Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

• Main Authors: Tais Basaco (Author), Stefanie Pektor (Author), Josue M. Bermudez (Author), Niurka Meneses (Author), Manfred Heller (Author), José A. Galván (Author), Kayluz F. Boligán (Author), Stefan Schürch (Author), Stephan von Gunten (Author), Andreas Türler (Author), Matthias Miederer (Author)
• Format: Book
• Published: MDPI AG, 2018-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with ¹⁷⁷Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization...